gbc-hpvac.com
Contact us
About company
GBC-HpVac focuses on the development of GBC-R1 as a preventive and therapeutic first-line therapy for asthma and related allergic diseases. GBC-HpVac holds an exclusive, worldwide license from the University of Zurich. GBC-HpVac was founded in 2016 and is headquartered in Geneva, Switzerland.
Unknown
Unknown
Not verified company
